PepTalk 2017
PepTalk 2017

Pipeline Two Header

Cambridge Healthtech Institute’s Fourth Annual
Antibody-Drug Conjugates
Engineering for Clinical Success
January 10-11, 2017 | Hilton San Diego Bayfront | San Diego, CA


With more than 30 ADCs in clinical trials, and more on the way, antibody-drug conjugates have reached an exciting point in development, particularly with the current next-generation strategies. Cambridge Healthtech Institute’s Antibody-Drug Conjugates conference reveals the engineering that has brought about today’s revolution, and examines how to design safe and effective ADCs. In addition, strategies for advancing ADCs to the clinic will be discussed along with considerations for clinical trial design. Analyzing ADCs to explore conjugation, stability, payloads and tumor penetration will also be addressed in this leading ADC event.

Preliminary Agenda  


MOVING ADCs INTO THE CLINIC

Peripheral Neuropathy with Microtubule Inhibitor Containing Antibody Drug Conjugates: Challenges and Perspectives in Translatability from Nonclinical Toxicology Studies to the Clinic

Nicola Stagg, Ph.D., Scientist/Toxicologist, Safety Assessment, Genentech

Clinical Pharmacology of vc-MMAE Antibody-Drug Conjugates: Platform Approach to Characterize Pharmacokinetics and Peripheral Neuropathy

Chunze Li, Ph.D., Senior Scientist, Therapeutic Area Lead for ADCs, Clinical Pharmacology, Genentech


ANALYTICAL STRATEGIES

An Integrated Multiplatform Bioanalytical Strategy for Antibody-Drug Conjugates: A Novel Case Study

Vangipuram S. Rangan, Ph.D., Senior Director, Protein Chemistry, Bristol-Myers Squibb Co.

Neutropenia Translation of ADC: Perspective from Mechanistic Modeling

Shangchiung Chen, Ph.D., Scientist, Clinical Pharmacology, Genentech


ENGINEERING ADCs for GREATER EFFICACY

MMETA – A Tubulysin Analog for Antibody-Drug Conjugates

Dorin Toader, Ph.D., Senior Scientist, Antibody Drug Conjugates, MedImmune LLC

In vitro and in vivo ADC Stability

Nathan Tumey, Ph.D., Associate Research Fellow, Pfizer


ADCs TO FIGHT CANCER

The Multi-Facets and Potentials of ADC in the Era of Immune-Oncology

David Miao, Ph.D., CSO, Concortis Biotherapeutics

Leveraging Ultra-Potent Toxins in Novel ADCs for Highly Effective Anti-Tumor Therapy

Ulf Grawunder, Ph.D., CEO & Founder, NBE-Therapeutics, Ltd.


INNOVATING ADCs

Multiparatopic and Multispecific Nanobody-Based Drug Conjugates

Carlo Boutton, Ph.D., Director, Technology & Information Management, Ablynx NV

 



For questions about the meeting, please contact:

Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
Phone: 781-972-5421
Email: mruberry@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com